NanoViricides to Present at D. Boral Capital Inaugural Global Conference, Highlighting Antiviral Drug Development
NanoViricides, a clinical-stage biotech company specializing in nanomedicine-based antiviral treatments, will participate in the D. Boral Capital Inaugural Global Conference, offering investors insights into its advanced drug candidates targeting respiratory viral infections and other diseases.
NanoViricides, a clinical-stage pharmaceutical company developing innovative broad-spectrum antiviral therapies, will present at the D. Boral Capital Inaugural Global Conference in New York City. Company President and Executive Chairman Anil R. Diwan is scheduled to host investor meetings, providing an opportunity to showcase the company's advanced drug development pipeline.
The company's lead drug candidate, NV-387, represents a significant advancement in antiviral treatment strategies. Designed as a broad-spectrum antiviral drug, NV-387 targets multiple respiratory viral infections, including respiratory syncytial virus (RSV), COVID-19, Long COVID, influenza, and MPOX/Smallpox infections. The company is currently positioning this candidate for Phase II human clinical trials.
NanoViricides' approach leverages host-mimetic nanomedicine technology, utilizing special purpose nanomaterials to create potentially more effective antiviral treatments. The company has established a strategic Memorandum of Understanding with TheraCour Pharma, Inc., which provides access to critical intellectual property and technological know-how.
In addition to NV-387, the company is developing NV-HHV-1, a drug candidate targeting Shingles, further demonstrating its commitment to addressing diverse viral infection challenges. The two COVID-19 specific candidates, NV-CoV-2 and NV-CoV-2-R, showcase the company's versatile approach to developing targeted antiviral therapies.
The conference presentation offers investors and industry stakeholders a valuable opportunity to gain insights into NanoViricides' innovative drug development strategy and potential future impact on managing viral infections.